Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491339 | 1.00 | HDAC1 (0.47) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1491470 | 0.91 | HDAC1 (0.46) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1491387 | 0.91 | HDAC1 (0.46) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| Tefinostat SCHEMBL1491466 | 0.90 | HDAC1 (0.48) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| Tefinostat SCHEMBL1491467 | 0.90 | HDAC1 (0.48) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| Tefinostat SCHEMBL1491564 | 0.90 | HDAC1 (0.48) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1491592 | 0.90 | HDAC1 (0.46) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1491590 | 0.90 | HDAC1 (0.46) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1491504 | 0.88 | HDAC1 (0.50) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL1491500 | 0.88 | HDAC1 (0.50) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | claimed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | claimed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | claimed |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2019-08-01 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| EP-1964577-B1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964578-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964577-A2 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | Chroma Therapeutics Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877098-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117567-A2 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | HDAC1 2532/4885HDAC6 2482/4885HDAC8 1758/4885 |
| US-20210361772-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | HDAC1 2532/4885HDAC6 2482/4885HDAC8 1758/4885 |
| US-20190231887-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | HDAC1 2532/4885HDAC6 2482/4885HDAC8 1758/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | HDAC1 9/4885HDAC6 1058/4885HDAC8 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.